



May 15, 2024

Division of Dockets Management
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: WITHDRAWAL OF CITIZENS PETITION Docket No. FDA-2019-P-3937

Dear Sir or Madam:

The undersigned submits a request to withdraw the petition under Docket No. FDA-2019-P-3937 to request that the Commissioner of Food and Drugs Administration (FDA) that FDA assign a Therapeutic Equivalence Evaluation Code ("TE Code") for the company's Fulvestrant Injection, 250 mg/5 ml (50 mg/ml) which FDA approved on August 19, 2019 under New Drug Application ("NDA") 210063.

Sincerely,

Brian Malkin

Brian Malkin
Associate General Counsel, Regulatory Law